Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Kalvista Pharmaceuticals Inc (KALV)
Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 344,423
  • Shares Outstanding, K 34,169
  • Annual Sales, $ 0 K
  • Annual Income, $ -82,340 K
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.72
Trade KALV with:

Options Overview Details

View History
  • Implied Volatility 82.18% ( -22.64%)
  • Historical Volatility 37.51%
  • IV Percentile 25%
  • IV Rank 21.62%
  • IV High 253.26% on 11/18/22
  • IV Low 34.99% on 07/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 175
  • Put/Call OI Ratio 1.07
  • Today's Open Interest 2,069
  • Open Int (30-Day) 1,581

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/23
See More
  • Average Estimate -0.92
  • Number of Estimates 4
  • High Estimate -0.68
  • Low Estimate -1.29
  • Prior Year -0.98
  • Growth Rate Est. (year over year) +6.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.82 +14.29%
on 05/03/23
10.95 -7.95%
on 05/23/23
+1.21 (+13.64%)
since 05/01/23
3-Month
6.26 +61.15%
on 03/22/23
10.95 -7.95%
on 05/23/23
+2.48 (+32.63%)
since 03/01/23
52-Week
4.12 +144.66%
on 10/20/22
17.06 -40.91%
on 09/02/22
+1.34 (+15.33%)
since 06/01/22

Most Recent Stories

More News
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced...

KALV : 10.08 (+3.38%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate...

KALV : 10.08 (+3.38%)
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 10.08 (+3.38%)
Here's Why You Should Invest in Larimar (LRMR) Stock Now

Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.

RETA : 91.13 (+1.20%)
KALV : 10.08 (+3.38%)
LRMR : 3.82 (+3.52%)
SRZN : 0.5880 (-5.16%)
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.

NKTR : 0.6150 (+2.36%)
KALV : 10.08 (+3.38%)
LRMR : 3.82 (+3.52%)
SRZN : 0.5880 (-5.16%)
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 10.08 (+3.38%)
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

NKTR : 0.6150 (+2.36%)
CPRX : 11.61 (-0.26%)
KALV : 10.08 (+3.38%)
JNCE : 1.8800 (-2.59%)
LRMR : 3.82 (+3.52%)
5 Stocks to Buy as the Drug Industry Rebounds in 2023

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

CPRX : 11.61 (-0.26%)
NKTR : 0.6150 (+2.36%)
KALV : 10.08 (+3.38%)
JNCE : 1.8800 (-2.59%)
LRMR : 3.82 (+3.52%)
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 145.98%: Read This Before Placing a Bet

The consensus price target hints at a 146% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend...

KALV : 10.08 (+3.38%)
KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

KALV : 10.08 (+3.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 10.89
2nd Resistance Point 10.56
1st Resistance Point 10.32
Last Price 10.08
1st Support Level 9.76
2nd Support Level 9.43
3rd Support Level 9.19

See More

52-Week High 17.06
Fibonacci 61.8% 12.12
Fibonacci 50% 10.59
Last Price 10.08
Fibonacci 38.2% 9.06
52-Week Low 4.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar